Reports
Reports
Sale
The global hemostats market size was valued at USD 2.9 billion in 2023, driven by increasing incidence of surgical procedures across the globe. The market is expected to grow at a CAGR of 6.4% during the forecast period of 2024-2032, with the values likely to rise from USD 3.1 billion in 2024 to USD 5.2 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
With the rising number of chronic diseases, surgical procedures have seen a significant upswing in recent years. As hemostats find relevant applications across various healthcare domains, there has been rising awareness and effectiveness of hemostats. The market is driven by an increasing influx of new products based on different formulations to address a variety of conditions in the patients. With technical advancements, there has been high research and preference for using nature-based ingredients to leverage their natural benefits. In addition, rising adoption of biopolymers and nanoparticles in hemostats is also expected to boost the market value in coming years.
New Product Launches to Meet the Rising Hemostats Market Demand
The growth of the market is driven by significant product launches that integrate innovative and multiple polymers to minimize immunological side-effects and potential risk of infections. In May 2023, Artivion announced that their Absorable Hemostatic System, PERCLOT received FDA approval for premarket application. This product has been acquired by Baxter to expand their active and passive hemostat portfolio. PERCLOT contains absorbable polysaccharide granules that expediate the intrinsic clotting cascade by rapidly absorbing water from the blood, resulting in a high concentration of platelets, red blood cells, and coagulation factors.
Increasing Prevalence for Natural Products
Researchers are working on fusing natural polymers with synthetic polymers to enhance the quality of hemostatic agents. For instance, fibroin, a silk protein, does not have hemostatic potential because it lacks functional groups that encourage clotting. However, porous films created through the electrospinning of silk fibroin can be co-processed with synthetic polymers to improve efficacy. In June 2023, Cresilon Inc., received U.S. FDA clearance for their new Cresilon Hemostatic Gel (CHG) which incorporates polymers derived from algae plants. As key companies continue to bring novel and improved solutions for the patients, the hemostats market size is predicted to increase exponentially.
Surge in Technical Integration to Provide Effective Solutions
Modern machines are being designed to mimic the body's internal mechanisms, functioning as artificial counterparts. The MIT engineers are working on developing a two-component system. When injected into the body it leads to blood clot formation at the site of internal injury. The research involves the use of nanoparticles, constructed from a biocompatible polymer known as PEG-PLGA functionalized with a peptide called GRGDS and a polymer that emulates the actions of fibrinogen, contributing to artificial clotting. Continuous upgradation and technological integration into the medical ecosystem are expected to boost hemostats market growth in the forecast period. As this technology proceeds, it may lead to the development of next-generation combination hemostats that offer not only effective hemostasis but also targeted and precise clotting at the molecular level.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product Type
Market Breakup by Instrument Type
Market Breakup by Formulation
Market Breakup by Application
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
With an advanced healthcare infrastructure, North America led the global hemostat market share in the historical period. The United States government has been making major efforts on enhancing healthcare solutions for defense forces. The United States Congress decided to allocate USD 15 million to set up a new “Combat Readiness-Medical Research Program (CRRP)”, which specifically targets on prompt responses to life-threatening injuries and medical diagnostics. This indicates a significant expansion in the hemostat market, as it finds a specialized host different from the generic healthcare ecosystem.
Europe is also experiencing a notable surge in the hemostat market. Medtrade Products Ltd., a leading healthcare company, has extended their European market presence through an exclusive agreement with Laubscher & Co AG to distribute the CELOX™ PPH Uterine Hemostatic Tamponade in Switzerland. This CE-certified solution is expected to reach more clinicians through Laubscher’s extensive network, with potential expansion to other regions and contributing to the hemostat market size.
The Asia Pacific region is anticipated to witness rapid growth. The increasing access to healthcare services and improved healthcare infrastructure in the region is a major factor impacting the growth of the hemostats market directly. As more individuals seek and receive surgical interventions, including various types of surgeries, there is a heightened demand for medical tools and supplies like hemostats.
In November 2023, Ethicon (Johnson & Johnson’s MedTech division) announced the approval of ETHIZIA, a hemostatic sealing patch composed of a unique synthetic polymer technology. To make the patch highly adaptable, it has been designed to get rolled, stuffed, or trimmed, making it suitable for minimally invasive as well as open surgeries. The patch showed high efficacy by stopping the bleeding in 30 seconds, an average of six times faster than other leading patches. The product is expected to launch in the EMEA in Q1 2024 along with key markets in North America, Asia-Pacific and Latin America.
The key features of the hemostats market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Instrument Type |
|
Breakup by Formulation |
|
Breakup by Application |
|
Breakup by Indication |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Hemostats Market Overview
3.1 Global Hemostats Market Historical Value (2017-2023)
3.2 Global Hemostats Market Forecast Value (2024-2032)
4 Global Hemostats Market Landscape
4.1 Global Hemostats Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Hemostats Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Instrument Type
4.2.3 Analysis by Formulation
5 Global Hemostats Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Hemostats Market Segmentation (2017-2032)
6.1 Global Hemostats Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Combination
6.1.3 Oxidized Regenerated Cellulose Based
6.1.4 Gelatine Based
6.1.5 Collagen Based Haemostat
6.2 Global Hemostats Market (2017-2032) by Instrument Type
6.2.1 Market Overview
6.2.2 Halstead Mosquito Hemostatic Forceps
6.2.3 Kelly And Crile Hemostatic Forceps
6.2.4 Rochester-Carmalt Hemostatic Forceps
6.3 Global Hemostats Market (2017-2032) by Formulation
6.3.1 Market Overview
6.3.2 Matrix and Gel Hemostats
6.3.3 Sheet and Pad Hemostats
6.3.4 Sponge Hemostats
6.3.5 Powder Hemostats
6.4 Global Hemostats Market (2017-2032) by Application
6.4.1 Market Overview
6.4.2 Orthopaedic
6.4.3 General surgery
6.4.4 Neurological surgery
6.4.5 Cardiovascular surgery
6.4.6 Reconstructive surgery
6.4.7 Gynaecological surgery
6.5 Global Hemostats Market (2017-2032) by Indication
6.5.1 Market Overview
6.5.2 Closure
6.5.3 Surgery
6.6 Global Hemostats Market (2017-2032) by End User
6.6.1 Market Overview
6.6.2 Ambulatory Centers
6.6.3 Hospitals
6.6.4 Clinics
6.6.5 Community Healthcare
6.6.6 Others
6.7 Global Hemostats Market (2017-2032) by Distribution Channel
6.7.1 Market Overview
6.7.2 Hospitals
6.7.3 Ambulatory Surgical Centers
6.7.4 Clinics
6.7.5 Online Channels
6.8 Global Hemostats Market (2017-2032) by Region
6.8.1 Market Overview
6.8.2 North America
6.8.3 Europe
6.8.4 Asia Pacific
6.8.5 Latin America
6.8.6 Middle East and Africa
7 North America Hemostats Market (2017-2032)
7.1 North America Hemostats Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Combination
7.1.3 Oxidized regenerated cellulose based
7.1.4 Gelatine based
7.1.5 Collagen based haemostat
7.2 North America Hemostats Market (2017-2032) by Instrument Type
7.2.1 Market Overview
7.2.2 Halstead Mosquito Hemostatic Forceps
7.2.3 Kelly And Crile Hemostatic Forceps
7.2.4 Rochester-Carmalt Hemostatic Forceps
7.3 North America Hemostats Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Hemostats Market (2017-2032)
8.1 Europe Hemostats Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Combination
8.1.3 Oxidized regenerated cellulose based
8.1.4 Gelatine based
8.1.5 Collagen based haemostat
8.2 Europe Hemostats Market (2017-2032) by Instrument type
8.2.1 Market Overview
8.2.2 Halstead Mosquito Hemostatic Forceps
8.2.3 Kelly And Crile Hemostatic Forceps
8.2.4 Rochester-Carmalt Hemostatic Forceps
8.3 Europe Hemostats Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Hemostats Market (2017-2032)
9.1 Asia Pacific Hemostats Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Combination
9.1.3 Oxidized regenerated cellulose based
9.1.4 Gelatine based
9.1.5 Collagen based haemostat
9.2 Asia Pacific Hemostats Market (2017-2032) by Instrument type
9.2.1 Market Overview
9.2.2 Halstead Mosquito Hemostatic Forceps
9.2.3 Kelly And Crile Hemostatic Forceps
9.2.4 Rochester-Carmalt Hemostatic Forceps
9.3 Asia Pacific Hemostats Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Others
10 Latin America Hemostats Market (2017-2032)
10.1 Latin America Hemostats Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Combination
10.1.3 Oxidized regenerated cellulose based
10.1.4 Gelatine based
10.1.5 Collagen based haemostat
10.2 Latin America Hemostats Market (2017-2032) by Instrument Type
10.2.1 Market Overview
10.2.2 Halstead Mosquito Hemostatic Forceps
10.2.3 Kelly And Crile Hemostatic Forceps
10.2.4 Rochester-Carmalt Hemostatic Forceps
10.3 Latin America Hemostats Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Hemostats Market (2017-2032)
11.1 Middle East and Africa Hemostats Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Combination
11.1.3 Oxidized regenerated cellulose based
11.1.4 Gelatine based
11.1.5 Collagen based haemostat
11.2 Middle East and Africa Hemostats Market (2017-2032) by Instrument Type
11.2.1 Market Overview
11.2.2 Halstead Mosquito Hemostatic Forceps
11.2.3 Kelly And Crile Hemostatic Forceps
11.2.4 Rochester-Carmalt Hemostatic Forceps
11.3 Middle East and Africa Hemostats Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Company Overview
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Stryker
17.2.1 Company Overview
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Integra LifeSciences
17.3.1 Company Overview
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Hemostasis, LLC
17.4.1 Company Overview
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Teleflex Incorporated
17.5.1 Company Overview
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Medtronic
17.6.1 Company Overview
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 B. Braun SE
17.7.1 Company Overview
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Johnson & Johnson Services, Inc.
17.8.1 Company Overview
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 BD
17.9.1 Company Overview
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Baxter
17.10.1 Company Overview
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Marine Polymer Technologies, Inc.
17.11.1 Company Overview
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Teleflex Incorporated
17.12.1 Company Overview
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Gelita Medical
17.13.1 Company Overview
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Anika Therapeutics, Inc.
17.14.1 Company Overview
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Mil Laboratories Pvt. Ltd.
17.15.1 Company Overview
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Hemostats Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 2.9 billion in 2023, driven by increasing incidence of surgical procedures across the globe.
The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032, likely to reach a market value of USD 5.2 billion by 2032.
The market demand is driven by the rising prevalence of road accidents, along with new product launches that cater to a diverse section of indications, along with improvements in the healthcare industry, increasing focus on reducing surgical and post-surgical spending, and the government's reimbursement policies.
The advent of new materials used to improve efficiency of products along with reducing the risk of infection and transmission diseases is the current market trend. For example, Cresilon Inc., launched a new Cresilon Hemostatic Gel (CHG) which incorporates polymers derived from algae plants.
Based on product types, the market is divided into combination, oxidized regenerated cellulose based, gelatine based and collagen-based hemostats.
Matrix and gel, sheet and pad, sponge, and powder are common formulations used in hemostats.
It includes Halstead Mosquito hemostatic forceps, Kelly and Crile hemostatic forceps, and Rochester-Carmalt hemostatic forceps.
Based on indication, it includes closure as well as surgery.
Common application areas include orthopedic, general, neurological, cardiovascular, reconstructive, and gynecological surgeries.
Major distribution channels include hospitals, ambulatory surgical centres, clinics, and online channels.
Major end users include ambulatory centres, hospitals, clinics, community healthcare and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Pfizer Inc., Stryker, Integra LifeSciences, Hemostasis, LLC, Teleflex Incorporated, Medtronic, B. Braun SE, Johnson & Johnson Services, Inc., BD, Baxter, Marine Polymer Technologies, Inc., Teleflex Incorporated, Anika Therapeutics, Inc., and Mil Laboratories Pvt. Ltd., and Gelita Medical.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.